Merck announced that its experimental MK-0518 significantly reduced HIV virus levels in a mid-stage clinical trial. The drug blocks an enzyme that is needed to allow the virus to penetrate a cell and was used in 35 patients over 10 days. Report
Merck announced that its experimental MK-0518 significantly reduced HIV virus levels in a mid-stage clinical trial. The drug blocks an enzyme that is needed to allow the virus to penetrate a cell and was used in 35 patients over 10 days. Report